Therapy Areas: Oncology
Piper Named Chief Financial Officer at Scorpion Therapeutics
23 November 2021 - - US-based oncology company Scorpion Therapeutics, Inc has appointed Brian Piper as the company's first chief financial officer, the company said.

Piper is a veteran biotech financial executive with over 25 years of experience, including serving as chief financial officer at two publicly traded biotech companies.

Prior to Scorpion, he served as chief financial officer at Prelude Therapeutics, where he helped lead the company through a successful initial public offering in 2020 and an underwritten follow-on offering in early 2021.

Previously, Piper served as chief financial officer at Aevi Genomic Medicine, previously known as Medgenics, between 2016 and 2019, and the vice president of Finance and Investor Relations between 2014 and 2016.

His time at Aevi Genomic Medicine was preceded by a 13-year career at Shire Pharmaceuticals, holding key roles in investor relations, corporate venture capital and numerous additional financial roles, including two years spent in Dublin, Ireland establishing Shire's geographic expansion strategies.

Early in his career, Piper also spent time with Celera Genomics and Otsuka Pharmaceuticals, Inc.

Piper received his M.B.A. from the University of Maryland and his B.B.A. from the University of Notre Dame.

Scorpion Therapeutics is an oncology company whose goal is to develop precision medicines.

To achieve this, Scorpion is applying expertise in medicinal and computational chemistry paired with chemical proteomics and latest advances in target biology to improve tumor targeting and access to previously "undruggable" targets for many cancer patients.


Related Headlines